NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
Holding NAMS?
Track your performance easily

NewAmsterdam Pharma Company (NAMS) Financial Statements

90 Followers

NewAmsterdam Pharma Company Financial Overview

NewAmsterdam Pharma Company's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; NewAmsterdam Pharma Company is scheduled to report earnings on November 11, 2024, and the estimated EPS forecast is $-0.50. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue$ 2.28M--$ 0.00$ 0.00
Gross Profit$ 2.28M----
EBIT$ -39.01M--$ -1.99M$ -344.62K
EBITDA$ -38.99M--$ -1.99M$ -344.62K
Net Income Common Stockholders$ -48.70M--$ -1.17M$ 1.38M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 430.71M$ 438.52M-$ 615.44K$ 788.04K
Total Assets$ 446.69M$ 531.58M-$ 138.90M$ 139.06M
Total Debt$ 562.00K$ 118.00K$ 0.00$ 0.00$ 0.00
Net Debt$ -430.15M$ -438.40M$ 0.00$ -615.44K$ -788.04K
Total Liabilities$ 59.25M$ 650.94M-$ 7.05M$ 6.03M
Stockholders Equity$ 387.44M$ -119.36M-$ 131.85M$ 133.03M
Cash Flow-
Free Cash Flow$ -54.19M--$ -172.60K$ -393.68K
Operating Cash Flow$ -53.98M--$ -172.60K$ -393.68K
Investing Cash Flow$ -209.00K----
Financing Cash Flow$ 4.66M--$ 0.00$ -45.00K
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History

NewAmsterdam Pharma Company Debt to Assets

NewAmsterdam Pharma Company Cash Flow

NewAmsterdam Pharma Company Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis